HELIOS Dr. Horst Schmidt Kliniken Wiesbaden GmbH
- Address
- Ludwig-Erhard-Strasse 100, Dotzheim, 65199 Wiesbaden, Germany
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden GmbH - Oncology Research Center
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden GmbH operates as a comprehensive oncology research center with extensive expertise in investigating novel therapeutic approaches across multiple cancer types. The facility demonstrates particular strength in precision oncology and targeted therapy trials, focusing on both solid tumors and hematologic malignancies. Their research portfolio encompasses early-phase dose-finding studies through advanced Phase III randomized controlled trials, contributing significantly to the development of next-generation cancer treatments.
- Breast cancer research including HER2-targeted therapies, triple-negative breast cancer immunotherapy combinations, and antibody-drug conjugates
- Gynecologic malignancies with focus on ovarian, endometrial, and cervical cancers, including maintenance therapy strategies and platinum-resistant disease
- Hematologic cancers encompassing acute myeloid leukemia, multiple myeloma, Hodgkin lymphoma, and diffuse large B-cell lymphoma
- Gastrointestinal and lung cancers investigating immunotherapy combinations, targeted therapies, and novel biomarker-driven treatment approaches
The center's research activities emphasize personalized medicine approaches, utilizing advanced biomarker selection including HER2 expression levels, hormone receptor status, genetic mutations, and tumor mutational burden. Their trials frequently incorporate companion diagnostics and innovative drug delivery systems, evaluating combination regimens that integrate immunotherapy, antibody-drug conjugates, and targeted small molecules to optimize patient outcomes across diverse oncologic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 70 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Technische Universitat Dresden3active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HELIOS Dr. Horst Schmidt Kliniken Wiesbaden GmbH
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy | Nord-Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. | Phase II | Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 70 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 9 | Unknown | 2016-11-07 | 2026-04-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.